Synarc builds clinical trials services with Danish merger
US-based provider of centralised imaging and molecular marker services, Synarc plans to expand into the field of clinical trials through a merger with the Denmark-based Center for Clinical and Basic Research (CCBR).
US-based provider of centralised imaging and molecular marker services, Synarc plans to expand into the field of clinical trials through a merger with the Denmark-based Center for Clinical and Basic Research (CCBR).
CCBR has expertise in implementing clinical research studies and it will become a wholly-owned subsidiary of Synarc.
"Combining with CCBR signals our intention to grow Synarc beyond our present focus as a medical imaging and molecular markers services company to a more complete and diversified clinical trial services organisation," said Gary Velasquez, Synarc's president and ceo.
Based in San Francisco, Synarc helps pharmaceutical industry clients to accelerate clinical trials and decrease the time, uncertainty and cost of drug development. The company currently manages more than 150 clinical trials at 1,500 sites worldwide and has offices in the US, Europe and Asia.
CCBR offers expertise in patient recruitment and data management for clinical trials and scientific publication of clinical trial results. Based in Copenhagen, CCBR operates clinical trial sites in Denmark, Poland, the Czech Republic, China, Romania, Lithuania, Brazil, and Estonia, and employs more than 200 researchers, technicians and support staff worldwide.
The transaction will not change leadership roles at either organisation. Dr Claus Christiansen will retain his position as CCBR's ceo.